FAK to the Rescue: Activated Stroma Promotes a “Safe Haven” for BRAF-Mutant Melanoma Cells by Inducing FAK Signaling
Open accessAbstract
Perhaps the most pressing need in cancer therapeutics is to understand drug resistance. In this issue of Cancer Cell, Hirata and colleagues show that melanoma-associated fibroblasts can drive resistance to the BRAF inhibitor PLX4720 by stimulating matrix production/remodeling, and, consequently, survival signaling in melanoma cells via β1-integrin, Src, and FAK.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Activation of FAK signaling has been proposed as a mechanism underlying resistance to targeted therapies.
“activation of FAK signaling has been proposed as a mechanism underlying resistance to target therapies, specifically because of its impacts on multiple aspects of the tumor microenvironment.[ 15, 16 ]”
From Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling (2021) · cites this paper as [16]
The citation lists haven’t been fetched yet
References 7 · Cited by 23
- Authors
- Frame, M. C., & Serrels, A.
- Affiliations
- Edinburgh Cancer Research (GB)
- Corresponding author
- Frame, Margaret C.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 27
- Issue
- 4
- Pages
- 429-431
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W1988810895
- Cited by
- 23
- References
- 7
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 3 · 2019: 5 · 2017: 3 · 2015: 5
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust (100282/Z/12/Z)
- Cancer Research UK (15703)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- BRAF-mutant melanoma, PLX4720, BRAF inhibitor resistance, focal adhesion kinase signaling, beta1 integrin, Src kinase, extracellular matrix remodeling, tumor microenvironment, drug resistance
- MeSH terms
- Animals, Humans, Melanoma, Drug Resistance, Neoplasm, Integrin beta1, Proto-Oncogene Proteins B-raf, Focal Adhesion Protein-Tyrosine Kinases, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
